Weeks after earning CEO’s stamp of approval, a Novartis skin drug loses head-to-head battle with standard of care

With a jam-packed pipeline to parse, Novartis chief Vas Narasimhan has helped investors out in the past by highlighting a few key programs his team thinks could be easy winners. One of those drugs has now hit the skids in two late-stage tests, losing some of its luster as...

Click to view original post